Recent Advances in Understanding Multiple Sclerosis

Dear Colleagues,

In the last few years, new insights have emerged on the pathogenesis and treatments of multiple sclerosis. A principal novelty has been exploring and evaluating chronic inflammation beyond what is detected with common, conventional techniques such as magnetic resonance imaging; therefore, broadening our knowledge on the pathogenetic mechanisms of chronic progressive multiple sclerosis, the pathological features of the disease (meningeal follicles, inflammation of chronic expanding lesions, cortical lesions), and identifying possible therapeutic targets are an active field of scientific research. Based on the role of B lymphocytes in the pathogenesis of multiple sclerosis, new drugs such as B cell depleting agents have been developed for progressive multiple sclerosis. Nevertheless, a drug for secondary progressive multiple sclerosis will be on the market soon. For these reasons, the future challenges will be to better identify the progression of the disease, to intercept the transitional forms, and to understand the target of treatment response in progressive patients.

We welcome articles providing new insights into

(i) humoral/clinical or digital biomarkers to early detect the onset or sustained disease progression;

(ii) markers of treatment response in relapsing and progressive patients with multiple sclerosis;

(iii) management of therapy switch;

(iv) novel clinical approaches to ameliorate symptoms of disease, especially in the progressive phase.

We welcome both solicited and unsolicited submissions that will contribute to this goal.

Prof. Simona Bonavita
Dr. Elisabetta Signoriello
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.